COMPARE · Reviewed August 3, 2026
FMS vs PACS
Verdict: Side-by-side breakdown using the Bull Rankings model. FMS scored 72.1, PACS scored 69.4 — FMS leads.
Compare another set
Different reporting periods. PACS's fundamentals are as of March 2026, but FMS's are as of December 2016 — a 113-month gap. Growth, margin and valuation figures below therefore describe different windows and aren't strictly like-for-like.
FMS
Fresenius Medical Care AG
72.1
$23.92 · $12.8B
fundamentals as of
Score gap
2.7
FMS leads
PACS
PACS Group, Inc.
69.4
$45.29 · $7.2B
fundamentals as of
The model, pillar by pillar (0–100 each)
FMS
stronger →← stronger
PACS
75
Qualityreturns · margins · balance sheet
60
75
Growthrevenue & earnings expansion
100
78
Valuevaluation vs sector peers
56
FMS is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
FMS
PACS
$1.1bC+
FCF
$151mC
+5.9%C+
Rev
+22.2%A-
0.78C+
D/E
3.36D
12.7xA
P/E
29.2xB
0.91B+
PEG
1.35B
Winner per row is the stronger grade in our model; a tie or a missing value shows no highlight.
Valuation · DCF cross-check
FMS
PACS
44% below
Price vs fair valuelower is cheaper
207% above
~-6%/yr
Growth the price implies10-yr FCF · lower = less priced in
~33%/yr
+58%
1-yr DCF upside
-68%
+77%
5-yr DCF upside
-67%
+110%
10-yr DCF upside
-66%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
FMS
Why this score
- Buying back stock
- Foreign reporter (EUR)
PACS
Why this score
- Diluting shareholders
- Short track record
The companies
FMSFresenius Medical Care AG
Why now
Medical Care Facilities · market cap $12.8b. 13% off the 52-week high of $27.64. PEG 0.91 — paying under fair value for the growth rate. 7 sell-side analysts rate this a Hold with a mean 1-yr target of $25.95 (implying +8% upside).
Moat
Net margin 24% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 12% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere.
Risk
Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
PACSPACS Group, Inc.
Why now
Medical Care Facilities · market cap $7.2b. 6% off the 52-week high of $48.00. Revenue growing +22%, comfortably above the S&P median. 6 sell-side analysts publish a mean 1-yr target of $52.67 (implying +16% upside).
Moat
ROE 24% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately.
Risk
D/E 3.36 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Net margin 4.5% is thin — operating leverage cuts both ways; input-cost inflation or pricing pressure hits the bottom line first.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.